#1AbCellera BUSINESS PRESENTATION DECEMBER 2020 Carl Hansen PhD Chief Executive Officer Andrew Booth MBA Chief Financial Officer#2DISCLAIMERS This presentation has been prepared by AbCellera Biologics Inc. ("we","pur" or the "Company"). The information set forth berein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this presentation unless stated otherwise, and neither the presentation, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof. This presentation includes forward-looking statements regarding our business, strategy, technology, ability to discover and deliver antibodies to our partners, strategic plans, acquisitions, partnerships, including the development and commercialization of any antibodies that we deliver to our partners, expected revenues that we may receive from our partnerships, market sizing and expectations, results from operations and other matters. Actual results could differ materially from those contained in any forward-looking statements as a result of various factors, including without imitation: the quality of our antibody discovery platform and technological capabilities and their acceptance by now and existing partners in our market, our ability to maintain or expand our current partnerships or enter into new partnerships: our dependence in recent periods on a limited number of partners for our revenue: the inherent uncertainty associated with biopharmaceutical drug development and the possibility that our partners do not further develop the drug candidates that we discover and deliver, or that our partners do not secure marketing approval or experience commercial success with respect to such candidates our ability to manage our current and future growth; our ability to capitalize on the investments that we have made and intend to make to our technology: our partners ability to achieve projected discovery and development milestones and other anticipated key events in the expected timelines or at all our ability to compete in the life sciences and biotech platform technology market our ability to protect our intellectual property and the other risk factors contained in the preliminary prospectus to which this offering relates. We undertake no obligation to update forward-looking statements as a result of new information of otherwise. AbCellera This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry. This data involves a number of assumptions and imitations and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions, and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk We have filed a registration statement on Form 5-1 (including a preliminary prospectus) with the Securities and Exchange Commission (the "SEC") for the offering to which this communication relates. The regstration statement has not yet become effective. Our common shares may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. Before you invest, you should read the preliminary prospectus and the other documents we file with the SEC for more complete information about us and this offering, You can obtain these documents for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, copies of the preliminary prospectus may be obtained from: Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, 6933 Louis Stephens Drive, Monivile, North Carolina 27560, United States. by telephone at (800) 221-1037, or by email at una [email protected]: Stifel, Nicolaus & Company, Incorporated. Attention: Prospectus Department. One Montgomery Street, Suite 3700. San Francisco, CA 94104 by telephone at (415) 364 2720, or by email at [email protected] Berenberg Capital Markets LLC. Attention: Investment Banking, 1251 Avenue of the American, 53rd Floor, New York, NY 10020, by telephone at (646) 949-9000, or by email at [email protected] SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at (800) 808-7525. ext. 6132, or by email at [email protected] or BMD Capital Markets Corp., 3 Times Square, New York, NY 10036, Attention: Equity Syndicate Department, by telephone at (800)414 3627, or by email at [email protected] This presentation shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.#3OFFERING SUMMARY ISSUER (TICKER] BASE OFFERING SIZE OPTION TO PURCHASE ADDITIONAL SHARES PRICE RANGE GROSS PROCEEDS USE OF PROCEEDS BOOKRUNNERS EXPECTED PRICING DATE LOCK-UP PERIOD AbCellera Biologics Inc. (NASDAQ: ABCL) 23 million common shares (100% primary) 15% (100% primary) or 3.45 million common shares $14.00-$17.00 per share $356.5 million (assuming midpoint of pricing range and excluding option to purchase additional shares) The Company intends to use the net proceeds from this offering to: • Invest in research and development efforts towards deepening the technology and expertise along technology stack: • Invest in building business development team and marketing solutions to new and existing partners; and • General corporate purposes, including working capital, operating expenses and capital expenditures. Credit Suisse, Stifel, Berenberg, SVB Leerink and BMO Capital Markets AbCellera December 10, 2020 (post-market close) 180 days for the Company, directors, officers, and substantially all securityholders COPYRIGHT © ARCELLESA#4INVESTOR HIGHLIGHTS TECHNOLOGY IS THE SUREST PATH TO A BETTER FUTURE. We believe the new frontier of technology lies at the interface of computation, engineering and biology. Triple-digit CAGR, profitable, cashflow positive² 1.19 2019 Centralized business model for $140B¹ antibody-based therapeutics market Full-stack Al-powered antibody discovery engine AbCellera 174 employees³; founded in 2012 94 antibody discovery projects³ AbCellera-discovered COVID-19 antibody authorized for emergency use in the US & Canada BACKED BY LEADING HEALTHCARE & TECHNOLOGY INVESTORS TO SOLVE BIOLOGICS DISCOVERY & DEVELOPMENT INCLUDING: OrbiMed DCVC Bio Viking Global Investors. Peter Thiel . Founders Fund Eli Lilly and Company University of Minnesota Presight Capital#5THE PROBLEM LIMITED TECH & LIMITED ACCESS LIMITS IMPACT Drug developers focus on getting one drug candidate to the finish line. The result is a chronic underinvestment in the technologies to make the process of drug development better. Drug development fails too often, takes too long and costs too much. ~$3 billion The average cost of drug development. + ~9.4 to 12 years AbCellera The time it takes an average antibody drug from initiation to approval. ~90% failure rate#6New technologies and a new business model are needed to lead antibody discovery and capture the antibody-based therapeutic market. +$118B 10.6% CAGR $143B $261B 2019 2025 Antibody Market +$16B 59.6% CAGR $18 2019 $178 2025 Cell Therapy Market THE MARKET BREAKING BOTTLENECKS IN A $140B+ ANTIBODY THERAPEUTICS MARKET.#7THE OPPORTUNITY ACCESS THE DATABASE OF NATURAL ANTIBODIES. Trrrr Tr rr rrrrrrrri ryrrs The immune system is a database that encodes nature's answers for fighting diseases and infections. But it's been challenging to access the database. Billions of unique antibodies inside each patient. Y Each is made by a single cell. Finding the best antibody finding the cell that makes it. يرلا AbCellera Powered by over 500 million years of evolution. Antibodies created by natural immune systems benefit from selection, quality assurance and optimization. -92% of approved antibody drugs are derived from natural immune systems.#8SCOPE SCALE ENABLING TECHNOLOGY THE SOLUTION: A UNIQUE COMBINATION OF HARDWARE, SOFTWARE & WETWARE Data clouds (dots) generated at each step fuel & compound insights about antibodies, revealing rare antibodies with the desired qualities SOURCE immune response FROM ANY SPECIES Optimized Immunization FROM ANY SPECIES. ANY TARGET Li SEARCH millions OF IMMUNE CELLS High-Throughput Single-Cell Screening TO SEARCH IMMUNE CELLS Customizable Functional & Bead-Based Assays FIND hundreds OF UNIQUE ANTIBODIES WITH DESIRED PROPERTIES Automated Single- Cell Genomics + Repertoire Profiling PERFORMED IN PARALLEL Single-Cell & Immune Repertore Sequencing ANALYZE dozens OF CANDIDATES WITH CHARACTERIZED PROPERTIES Customized Bioinformatics + Visualization OF SELECT CHAINS ITERATIVE Lineage & Clonal Famey Mapping ENGINEER a few FULLY CHARACTERIZED & VALIDATED LEAD CANDIDATES High-Throughput Expression + alytics OF HIGH-CONFIDENCE PAIRED CHAINS +44 Is u r AbCellera DELIVER Lead Antibody Candidate(s) FOR DEVELOPMENT Y#9THE TECH STACK: AN AI-POWERED PLATFORM BUILT ON REAL WORLD DATA DEEP TECH, COMPLEX INTEGRATION, AT SCALE. Many life sciences companies have technologies that focus on one or a limited number of steps in the process. We believe we uniquely integrate proprietary technologies that address each of these steps. SOURCE Immunization ABCELLERA KNOW-HOW Humanized Mice POWERED BY Trianni Mouse ACQUISITION POWERED BY Alloy ATX-Gx™M IN-LICENSED Ligand, Ablexis SEARCH Single-Cell Secretion Assay ARCELLERA PATENTED TECHNOLOGY Berkeley Lights FIND Repertoire Sequencing & Analysis POWERED BY Lineage Biosciences Ig-Seq Platform ACQUISITION ANALYZE 10X Genomics, Adaptive Mapping & Visualization ABCELLERA COMPUTATIONAL ENGINE POWERED BY 8 Examples of companies with technologies at different steps of our technology stack include: CELTUM ITERATIVE I ENGINEER Biophysical Properties Analysis ANCELLERA KNOW-HOW AbCellera • Multispecific Development POWERED BY OrthoMab Bispecific Platform ACQUISITION Genmab, Zymeworks#10increasing TECHNOLOGY ADVANTAGE more FACILITIES + TECHNOLOGY ACQUISITIONS DEMOCRATIZE THE INDUSTRY. THE BUSINESS STRATEGY more TEAM KNOW-HOW more CAPABILITIES more ACCESS CENTRALIZED more smarter AI OPPORTUNITIES ANTIBODY DISCOVERY OPERATING SYSTEM more BUSINESS GROWTH more PARTNERSHIPS more DATA + LEARNING AbCellera#11DISCLOSED PARTNERSHIPS Lilly GILEAD Autolus KODIAK gsk MERCK BILL & MELINDA GATES foundation DENALI NOVARTIS teva Ablynx A SANOFI COMPANY SANOFI Lyell Pfizer XInvetx + UNDISCLOSED PARTNERS including large cap pharmaceutical and biotechnology companies of all sizes DARPA AbCellera igm biosciences#12CASE STUDY: COVID-19 BAMLANIVIMAB AUTHORIZED FOR EMERGENCY USE IN THE U.S. & CANADA. YLOSTIPANO bamlanivimab injection 700 mg/20 ml (35 mg/ml) NDC:0002-7910-01 bamlanivimab injection 700 mg/20 mL (35 mg/mL) For intravenous infusion Only Must diute before use Single-Dose Via Discard Unused Partion For use under Emergency Use Authorization (EUA) Lilly AbCellera Based on Phase 2 monotherapy trial results 72% risk reduction in hospitalizations compared to placebo in patients recently diagnosed with mild-to- moderate COVID-19#13PARTNERSHIP BUSINESS MODEL HELP EVERYONE & SHARE IN THE SUCCESS. target PARTNER BIOTECH, PHARMA ABCELLERA mAb Pre-clinical DISCOVERY RESEARCH FEES Near-term revenue from research payments (capital efficient) Phase 1 Phase 2 Phase 3 Approval MILESTONES Multimillion dollar potential clinical and commercial milestone payments Building a diversified portfolio of milestones & royalties (primary value driver) AbCellera Commercial Sale ROYALTIES Majority of risk-adjusted value from royalty on commercial therapeutic sales#14HISTORICAL PERFORMANCE: KEY PERFORMANCE INDICATORS* PARTICIPATING IN THE SUCCESS OF FUTURE ANTIBODY THERAPEUTICS. 15 10 # of Discovery Partners + WITH DOWNSTREAM PARTICIPATION - WITHOUT DOWNSTREAM PARTICIPATION 2014 2015 2016 2017 2018 2019 2020 Q3 end 100 60 20 Cumulative # of Programs Under Contract + WITH DOWNSTREAM PARTICIPATION - WITHOUT DOWNSTREAM PARTICIPATION 2014 2015 2016 2017 2018 2019 2020 Q3 end Historical results are not necessarily indicative of future results 2 288 28 & 29 20 0 Cumulative # of Program Starts AbCellera 2014 2015 2016 2017 2018 2019 2020 Q3 end#15HISTORICAL PERFORMANCE: MILESTONES TRIPLE-DIGIT CAGR, PROFITABLE & CASHFLOW POSITIVE¹. Revenue USD $0 Total Employees 2014 Closed-$900K Seed Round $0.9M Milestones 2015 Secured first discovery partnership contract 11 Financial statements pressed under 1. GAAP $2.2M 2016 29 $3.5M 2017 Approved funding for $30M DARPA P3 Project Acquired Lineage Biosciences Ig-Seq Platform $8.8M 2018 Closed $10M Series A led by DCVC Bio Opened 21,000 sqft facility $11.6M 58.4M 2019 200% 2010 03 106 Awarded foundational patents for microfluidic screening assays for antibodies $25.2M 174 2020 Q3 end Closed $105M Series A2 Approved funding for $126M Government of Canada Project Potential antibody therapy for COVID-19 entered human testing In-licensed Alloy ATX-Gx™ Acquired OrthoMab Bispecific Platform Acquired Trianni Mouse" AbCellera#16LEADERSHIP TEAM TEAM IS EVERYTHING. Our founder-led team of 174 employees* includes 45 engineers and data scientists, 81 scientists and 48 business professionals. Board of Directors R&D Ester Falconer, PhD Head of Research & Development Carl Hansen, PhD Chairman & Chief Executive Officer Partnerships Véronique Lecault, PhD John Hamer, PhD Director & Chief Director Operating Officer Kathleen Lisaingo, PhD Sherie Duncan, PhD Senior Manager, Group Leader, Cell Screening Programs & Partnerships Difficult Targets Adam Clarke, PhD VP Channel Bio. John Montalbano, CFA Director Translational Research Bo Barnhart, PhD Scientific Director Communications Tiffany Chiu Senior Director Peter Thiel Director Operations Michael Hayden, MB, ChB, PhD, FRCP (C), FRSC, CM, OBC Director Finance & BD Véronique Lecault, PhD Andrew Booth, MBA Director & Chief Chief Financial Officer Operating Officer AbCellera Legal & IP Tryn Stimart, JD Chief Legal Officer#17AbCellera THANK YOU Carl Hansen PhD Chief Executive Officer Andrew Booth MBA Chief Financial Officer#18TECHNOLOGY STACK#1901 SOURCE TECH STACK#20SOURCE: IMMUNIZATION OPTIMIZATION CONTROL IMMUNITY TO GENERATE BETTER DIVERSITY We aim to generate and access a high-quality universe of antibodies for any target. M Proprietary Immunization Methods Any Source Any Tissue TRIANNI an Abtellera company ALLOY THERAPEUTICS Human Antibodies from Rodents SOURCE SEARCH FIND AbCellera ANALYZE ENGINEER We trigger immune responses from any species with the goal of generating the best antibodies, with the most diversity.#21TECH STACK 02 SEARCH#22DEEPLY SEARCH ANY ANTIBODY RESPONSE WITH MICROFLUIDIC SINGLE-CELL ASSAYS 1251 張 0000 0000 0000 0000 Multiple credit card-sized devices integrating 512K miniaturized chambers per setup to screen millions of B cells. SOURCE SEARCH FIND ANALYZE ENGINEER <1nL single-cell chamber x 256,000 per device Each B cell is tested for the secretion of antibodies that bind to specific antigens. Positive binding is detected by high-throughput fluorescence microscopy and processed using machine vision. EXEMPLARY ASSAY: BEAD-BASED MULTIPLEX Secreted Antibodies Antibody- Secreting Cell Brightfield ASSAY DESIGN SIDE VIEW READOUT TOP VIEW Optical Bead Encoding Labelled Secondary Antibodies Antigen-Coated Beads (A. B. C) Binding with Encoding Mask#23SEARCH: HIGH-THROUGHPUT SINGLE-CELL SCREENING SEARCH FOR ANY ANTIBODY PROPERTY Secreted Antibodies Antibody Secreting Cel Secreted Antibodies Antibody Secreting Cl LIVE-CELL لال Oooo AFFINITY Labeled Secondary Antibodies Antigen Expressing Cells Labeled Antigens G-Coated Antibodies Antibody Secreting Coll Secreted Antibodies Antibody Secreting Cut SPECIFICITY LIGAND-BINDING Labeled Ligands Laberied Antigens IgG Coated Dead Labeled Secondary Antibodies Antigen Coated Secreted Antibodies Antibody Secreting Coll Secreted Antibodies Antibody Secreting Cet Antigen Coated Beads SOURCE SEARCH FIND CROSS-REACTIVITY COMBINATION AbCellera ANALYZE ENGINEER Labelled Secondary Antibodies Antigen-Coated Beads Labelled Secondary Antibodies Antigen Expressing Cels#24TECH STACK 03 FIND#25FIND: SINGLE-CELL GENOMICS & REPERTOIRE PROFILING SINGLE-CELL LEAD LINEAGE TREE PLUS Germline Single-Cell Single-Cell / Repertoire Repertoire Inferred ADDITIONAL LEADS LINEAGE TREE @ SOURCE SEARCH FIND AbCellera ANALYZE ENGINEER AMPLIFY OPTIONS FROM A SINGLE-CELL LEAD THROUGH REPERTOIRE SEQUENCE MAPPING POWERED BY 8 CELIUM#2604 ANALYZE TECH STACK#27ANALYZE: HIGH-THROUGHPUT EXPRESSION+ BIOANALYTICS CELLS TO DATA. DATA TO PROTEIN. PROTEIN TO DATA. Industrialized Genomics, Cloning & Expression High-throughput robotics with optimized protocols allows thousands of samples per week. SOURCE SEARCH FIND AbCellera ANALYZE ENGINEER#28ANALYZE: HIGH-THROUGHPUT EXPRESSION + BIOANALYTICS A MULTI-DIMENSIONAL DATA CLOUD FOR EACH ANTIBODY. Automation & Analytics Generate virtual data clouds around each antibody to assess function and biophysical properties needed for rapid drug development. HIGH-THROUGHPUT EXPRESSION PURITY 1 4000 I BINDING VALIDATION STABILITY SOURCE FUNCTIONAL VALIDATION 00000 ●●●00 00... 00000 SEARCH OLIGOMERIZATION FIND EPITOPE BINNING AFFINITY AbCellera ANALYZE ENGINEER S U₁ r#29ANALYZE: CUSTOMIZED BIOINFORMATICS + ANTIBODY VISUALIZATION COMPILE, COMPUTE, AND VISUALIZE BIG DATA. Custom-built data collection across entire pipeline • Partnership model feeds unique multi- . dimensional database • Backend computation based on Al, computational structure, and data analytics • Front-end interface, CeliumTM, connects scientists to data through interactive visualization SOURCE SEARCH FIND CELIUM AbCellera ANALYZE ENGINEER heavy chain antibody pair light chain#3005 ENGINEER TECH STACK#31ENGINEER: PROTEIN ENGINEERING ENGINEER FIT-FOR-PURPOSE LEAD ANTIBODY CANDIDATES. Our protein engineering tool-kit supports next-generation antibody therapeutics, such as VHH constructs, humanization, deimmunization, optimization, reformatting, and most recently, bispecific antibodies that enable the following therapeutic modalities: CELLULAR CO- LOCALIZATION RECEPTOR HETERODIMERIZATION PROTEIN SCAFFOLDING SOURCE SEARCH FIND PK / PD MANIPULATION AbCellera ANALYZE ENGINEER#32IMPROVE DEVELOPMENT OF BISPECIFICS WITH CLINICALLY-VALIDATED PROTEIN Diverse panels. ENGINEERING TECHNOLOGY. Develop bispecifics with native IgG-like format. Optimized discovery yields large and diverse panels • Full IgG format with other additional engineering options SOURCE SEARCH FIND ANALYZE ENGINEER • Predictable development from native antibody format I Stable + manufacturable. Standardized mAb protocols Efficient Proven platform. 0 0 Technology validated in the clinic AbCellera 3#33Example mutations at a heavy-light chain (Fab) interface: V₁ SOURCE SEARCH COMBINE ANY TWO ANTIBODIES TO CREATE NATIVE BISPECIFICS. 5 FIND ANALYZE ENGINEER STANDARD PARENTAL IgG's BISPECIFIC IgG AbCellera 3 protein-protein interfaces with 1 to 4 mutations per domain to ensure correct and stable pairing of multiple heavy (VHC) and light (V₁ C₁) chains#34INTELLECTUAL PROPERTY#35INTELLECTUAL PROPERTY GLOBAL INTELLECTUAL WITH FOUNDATIONAL • 40+ applications worldwide • 15 patent families 35* PATENTS PROPERTY PORTFOLIO PATENTS. Methods for Assaying Expect to expire 2034 Owned or exclusively licensed Immune Rep Seq Expect to expire 2034 EXEMPLARY PATENT GROUPS Foundational claims on high-throughput single-cell secretion assays with application to antibody discovery & clone selection COVID-19 Expect to expire no earlier than 2040 AbCellera#36TECH STACK EXPANSION#37EXPANSION: RESEARCH & DEVELOPMENT EXPAND THE BREADTH & DEPTH OF OUR TECH STACK UNLOCK THE LARGEST CLASS OF DRUG TARGETS A New ion channel and GPCR (G protein-coupled receptors) technology for antigen design and immunization INTEGRATE FULL CMC+ GMP MANUFACTURING Cell line development + AbCellera GMP manufacturing facility for production of biologics for clinical testing#38EXPANSION: GMP MANUFACTURING THE GOAL: TARGET TO FILL-FINISH IN ONE YEAR. Future plans for deepening the tech stack include: Cell line development + GMP manufacturing facility for production of biologics for clinical testing AbCellera FINANCIAL POST AbCellera Receives $126 Million from the Government of Canada to Discover Solutions for COVID-19 and Build a Manufacturing Facility for Antibody Drugs AbCellera's world-leading drug discovery technology identifies antibodies for potential use in drugs to treat and prevent COVID-19 This facility, which is partly funded by a $126M grant by the Government of Canada, will be the first in Canada capable of going from a patient sample to manufacturing antibodies for clinical testing